Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703102 · ClinicalTrials.gov registry record · Phase 2
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT03703102 is a Phase 2 study that has completed, run by Kyowa Kirin. The registered enrollment target is 274 participants.
The verdict
NCT03703102, a Phase 2 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Interventions
- DRUG Placebo
- DRUG KHK4083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03703102
The ClinicalTrials.gov registry entry for NCT03703102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03703102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03703102 about?
NCT03703102 is a clinical study titled "Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis". A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
What is the current status of trial NCT03703102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2018-10-22. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT03703102?
The interventions under investigation include: Placebo (DRUG), KHK4083 (DRUG).
Who is sponsoring clinical trial NCT03703102?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.